[
  {
    "ts": "2025-11-10T13:55:00+00:00",
    "headline": "AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer",
    "summary": "OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the 40th Annual SITC Meeting on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy with up to six treatment cycl",
    "url": "https://finance.yahoo.com/news/aim-immunotech-details-upmc-abstract-135500588.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "7f91c66c-ba90-3148-ae69-da38a5d9e7b9",
      "content": {
        "id": "7f91c66c-ba90-3148-ae69-da38a5d9e7b9",
        "contentType": "STORY",
        "title": "AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer",
        "description": "",
        "summary": "OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the 40th Annual SITC Meeting on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy with up to six treatment cycl",
        "pubDate": "2025-11-10T13:55:00Z",
        "displayTime": "2025-11-10T13:55:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/3c34f5042d0444d8a15493a212dc7a7f",
          "originalWidth": 753,
          "originalHeight": 402,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w9E.7KpDMw2q6tN.EtcY9w--~B/aD00MDI7dz03NTM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3c34f5042d0444d8a15493a212dc7a7f.cf.webp",
              "width": 753,
              "height": 402,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/43LBgV9Cpb0dcXxHYuW4fQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3c34f5042d0444d8a15493a212dc7a7f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/aim-immunotech-details-upmc-abstract-135500588.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/aim-immunotech-details-upmc-abstract-135500588.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "0A4Y.L"
            },
            {
              "symbol": "AIM"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]